Lipodystrophy syndrome and cardiovascular risk factors in children and adolescents infected with HIV/AIDS receiving highly active antiretroviral therapy

Jornal de Pediatria

Volumn 86, Issue 1, 2010, Pages 27-32

  Werner, Maria Luiza Falci ^a   Pone, Marcos V Da S ^a,b   Fonseca, Vânia M ^a,c   Chaves, Célia R M De M ^a,d  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^c STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Adolescents; Cardiovascular diseases; Children; HIV; Lipodystrophy

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LAMIVUDINE; LIPID; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TRIACYLGLYCEROL; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ARTICLE; BODY BUILD; BODY FAT DISTRIBUTION; BRAZIL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHILD; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL INTAKE; CLINICAL ARTICLE; DIETARY INTAKE; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID BLOOD LEVEL; LIPODYSTROPHY; MALE; NUTRITIONAL STATUS; PEDIATRICS; PRESCHOOL CHILD; PREVALENCE; SCHOOL CHILD; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 77649218744     PISSN: 00217557     EISSN: None     Source Type: Journal    
DOI: 10.2223/JPED.1961     Document Type: Article

References (30)

1. World Health Organization. Weekly Epidemiological Record [website]. Global situation of the HIV/AIDS pandemic. 2003;50:425-32. http://www.who.int/ wer/2003/en/wer7850.pdf. Access: 06/07/2004.
2. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 1998;351:1881-3.
3. McGill HC Jr, McMahan CA. Determinants of atherosclerosis in the young. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Am J Cardiol. 1998;82:30T-36T.
4. Leonard EG, McComsey GA. Metabolic complications of antiretroviral therapy in children. Pediatr Infect Dis J. 2003;22:77-84.
5. Tanner JM. Fetus into man-physical growth from conception to maturity. Cambridge: Harvard University Press; 1990.
6. Centers for Disease and Prevention. [website] CDC Growth Charts. http://www.cdc.gov/growthcharts. Access: 03/09/2003.
7. Frisancho AR. New norms of upper limb fat and muscle areas for assessment of nutritional status. Am J Clin Nutr. 1981;34:2540-5.
8. Jaquet D, Lévine M, Ortega-Rodriguez E, Faye A, Polak M, Vilmer E, et al. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS. 2000;14:2123-8.
9. Giuliano IC, Caramelli B, Pellanda L, Duncan B, Mattos S, Fonseca FH. I diretriz de prevenção da aterosclerose na infância e na adolescência. Arq Bras Cardiol. 2005;supl 6:3-36.
10. Miller O. Laboratório para o clínico. Rio de Janeiro: Atheneu; 1995.
11. Williams CL, Hayman LL, Daniels SR, Robinson TN, Steinberger J, Paridon S, et al. Cardiovascular health in childhood: A statement for health professionals from the Committee on Atherosclerosis, Hypertension and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2002;106:143-60.
12. Institute of Medicine. Dietary Reference Intakes for Energy, Carboydrates, Fiber, Fat, Fatty Acids, Cholesterol, Proteins, and Amino Acids (macronutrients). Washington: National Academy Press; 2002.
13. World Health Organization (WHO). Nutrient requirements for people living with HIV/AIDS: report of a technical consultation. Geneva: WHO; 2003.
14. Miller TL, Mawn BE, Orav EJ, Wilk D, Weinberg GA, Nicchitta J, et al. The effect of protease inhibitor therapy on growth and body compositions in immunodeficiency virus type-1 infected children. Pediatrics. 2001;107:E77.
15. Guillén S, Ramos JT, Resino R, Bellón JM, Muñoz MA. Impact on weight and height with the use of HAART in HIV-infected children. Pediatr Infect Dis J. 2007;26:334-8.
16. Fiore P, Donelli E, Boni S, Pontali E, Tramalloni R, Bassetti D. Nutritional status changes in HIV-infected children receiving combined antiretroviral therapy including protease inhibitors. Int J Antimicrob Agents. 2000;16:365-9.
17. Nachman SA, Lindsey JC, Moye J, Stanley KE, Johnson GM, Krogstad PA, et al. Growth of human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J. 2005;24:352-7.
18. Sarni RO, de Souza FI, Battistini TR, Pitta TS, Fernandes AP, Tardini PC, et al. Lipodystrophy in children and adolescents with acquired immunodeficiency syndrome and its relationship with the antiretroviral therapy employed. J Pediatr (Rio J). 2009;85:329-34.
19. Tassiopoulos K, Williams PL, Seage GR 3rd, Crain M, Oleske J, Farley J, et al. Association of hypercholesterolemia incidence with antiretroviral treatment, including protease inhibitors, among perinatally HIV-infected children. J Acquir Immune Defic Syndr. 2008;47:607-14.
20. Salas-Salvadó J, García-Lorda P. The metabolic puzzle during the evolution of HIV infection. Clin Nutr. 2001;20:379-91.
21. Kim JY, Zaoutis T, Chu J, Zhao H, Rutstein R. Effects of highly active antiretroviral therapy (HAART) on cholesterol in HIV-1 infected children: a retrospective cohort study. Pharmacoepidemiol Drug Saf. 2009;18:589-94.
22. Temple ME, Koranyi KI, Nahata MC. Lipodystrophy in HIV-infected pediatric patients receiving protease inhibitors. Ann Pharmacother. 2003;37:1214-8.
23. Lainka E, Oezbek S, Falck M, Ndagijimana J, Niehues T. Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy. Pediatrics. 2002;110:e56. http://pediatrics.aappublications.org/cgi/content/full/110/5/e56. Access: 02/03/2004.
24. dos Santos MG, Pegoraro M, Sandrini F, Macuco EC. Fatores de risco no desenvolvimento da aterosclerose na infância e adolescência. Arq Bras Cardiol. 2008;90:301-8.
25. Dubé MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613-27.
26. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem. 2000;275:20251-4.
27. Desai N, Mullen P, Mathur M. Lipodystrophy in pediatric HIV. Indian J Pediatr. 2008;75:351-4.
28. Viganò A, Mora S, Testolin C, Beccio S, Scheneider L, Bricalli D, et al. Increased lipodystrophy is associated with increased exposure to highly active antirretroviral therapy in HIV-infected children. J Acquir Immune Defic Syndr. 2003;32:482-9.
29. Sharma TS, Kinnamon DD, Duggan C, Weinberg GA, Furuta L, Bechard L, et al. Changes in macronutrient intake among HIV-infected children between 1995 and 2004. Am J Clin Nutr. 2008;88:384-91.
30. Almeida LB, Giudici KV, Jaime PC. Consumo alimentar e dislipidemia decorrente da terapia antirretroviral combinada para infecção pelo HIV: uma revisão sistemática. Arq Bras Endocrinol Metab. 2009;53:519-27.